▎药明康德
该研发中心将进一步提升药明康德原料药工艺开发能力，为各类合成分子提供创新解决方案，满足不断增长的市场需求
近日，药明康德宣布其位于江苏常州的全新研发中心正式启用，进一步提升小分子、寡核苷酸、多肽及复杂化学偶联药物开发能力。该研发中心占地13.4万平方米，在进一步提升药明康德原料药工艺开发能力，更加高效地支持所有合成分子的生产需求的同时，能够更好地降本增效、保护环境。
药明康德常州新研发中心首栋启用的WuXi TIDES研发大楼，专注于寡核苷酸、多肽及复杂化学偶联药物的工艺开发和分析研究
该研发中心距公司已经投产的常州原料药生产基地仅15分钟车程，可实现从研发到生产的无缝衔接。此外，该研发中心可为合作伙伴提供一流的工艺研发和分析服务，满足从临床前、临床到商业化阶段的项目需求。作为药明康德全球研发和生产网络的重要组成部分，该研发中心将为小分子药物CRDMO平台合全药业以及寡核苷酸和多肽CRDMO平台WuXi
TIDES提供重要支持。
常州研发中心包括６栋研发大楼，全部投入运营后将配备超170个专业实验室，可容纳大约3000名研发人员。随着研发中心启用，首栋研发大楼正式投入运营。该研发楼占地1.5万平方米，专注寡核苷酸、多肽以及各种复杂化学偶联药物的原料药工艺开发，并特别配备专门的溶剂输送管道、工艺用水再生系统、通风橱红外感应系统等设施，以进一步提升研发效率，增强可持续性，确保安全作业。目前，约500位科研人员已经入驻研发大楼，协同各类工艺研发及分析先进设备，可以更好地赋能寡核苷酸、多肽及复杂化学偶联药物的开发。此外，实验室采用模块化设计，进一步整合工作流程，并充分运用自动化及数字化控制，实现了更快的数据周转率及更高的工作效率。药明康德联席首席执行官陈民章博士表示：“新的研发中心能够进一步增强我们的端到端CRDMO平台能力，为合作伙伴提供更好、更高效的创新解决方案，覆盖从药物发现，到临床前和临床阶段药物开发，以及商业化生产的全流程。我们将持续携手全球合作伙伴加快新药开发进程，推动更多新药、好药早日问世，惠及病患。”
药明康德（股票代码：603259.SH/2359.HK）为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美等地均设有运营基地。药明康德通过独特的“CRDMO”和“CTDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、精准医疗研发、测试和生产等领域。2024年，药明康德连续第四年被MSCI评为ESG（环境、社会及管治）AA级。目前，公司的赋能平台正承载着来自全球30多个国家的6,000多家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。
WuXi AppTec Opens New R&D Center in Changzhou, ChinaNew
facility enhances the Company’s drug substance process R&D capacity
to drive innovation across all synthetic modalities and meet growing
global demand.WuXi
AppTec announces the recent opening of its new R&D center in
Changzhou, China, significantly expanding its capabilities in developing
advanced therapies covering small molecules, oligonucleotides, and
peptides as well as complex synthetic conjugates. This 33-acre campus
offers a flexible design, strengthening the Company’s drug substance
process research and development service offerings with increased
capacity and accelerated timelines, while reducing costs and
environmental impact.First operational building dedicated to API development for oligonucleotides, peptides, and complex synthetic conjugates
Strategically
located just 15 minutes from our existing Changzhou API manufacturing
site, the new R&D Center is a critical R&D hub for both WuXi
STA, the Company’s small molecule CRDMO platform, and WuXi TIDES, which
delivers oligonucleotide and peptide CRDMO services. The proximity
facilitates seamless collaboration between R&D and manufacturing;
the Center’s state-of-the-art capabilities integrate process R&D and
analytical services to support projects from preclinical through
commercialization.
Designed
with six R&D buildings, upon full operation, the Center will
accommodate approximately 3,000+ scientists with 170+ specialized
laboratories. The first
operational building, dedicated to API development for oligonucleotides,
peptides, and complex synthetic conjugates, spans over 160,000 square
feet. Its innovative design specifically supports development for
“TIDES” Drugs with features such as specialized solvent pipelines,
reclaimed process water systems, and infrared-activated fume hoods to
enhance efficiency, sustainability, and safety. Currently, the first
operational building houses 500 scientists. It offers a comprehensive
suite of services with most advanced process and analytical technologies
all designed to meet the complex demands of oligonucleotide and peptide
drug development. The modular lab integrates essential workflows with
latest digitalization and automation controls to achieve faster data
turnaround and higher efficiency. “This
new R&D center reinforces our ongoing commitment to supporting
customers as they advance global health,” said Dr. Minzhang Chen, Co-CEO
of WuXi AppTec. “By strengthening our end-to-end CRDMO capabilities for
all synthetic modalities, we further empower our partners with
comprehensive solutions from discovery through commercialization, and a
faster, more streamlined pathway to market. Together, we’re dedicated to
accelerating more innovative therapies to patients worldwide.”
As
a global company with operations across Asia, Europe, and North
America, WuXi AppTec provides a broad portfolio of R&D and
manufacturing services that enable the global pharmaceutical and life
sciences industry to advance discoveries and deliver groundbreaking
treatments to patients. Through its unique business models, WuXi
AppTec’s integrated, end-to-end services include chemistry drug CRDMO
(Contract Research, Development, and Manufacturing Organization),
biology discovery, preclinical testing and clinical research services,
advanced therapies CTDMO (Contract Testing, Development and
Manufacturing Organization), helping customers improve the productivity
of advancing healthcare products through cost-effective and efficient
solutions. WuXi AppTec received an AA ESG rating from MSCI for the
fourth consecutive year in 2024, and its open-access platform is
enabling more than 6,000 customers from over 30 countries to improve the
health of those in need – and to realize the vision that "every drug
can be made and every disease can be treated."
